Diagnosis and management of aspergillosis in the Netherlands: a national survey
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMC s) and eight non‐academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMC s. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high‐risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Self-citationVerweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
Self-citationProspective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus
van der Linden, J. W. M., Arendrup, M. C., Warris, A., Lagrou, K., Pelloux, H., Hauser, P. M., Chryssanthou, E., Mellado, E., Kidd, S. E., Tortorano, A. M., et al. (2015) · Emerging Infectious Diseases · doi:10.3201/eid2106.140717 · Cited by 371
Self-citationvan der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342
Self-citationDenning, D. W., Park, S., Lass-Florl, C., Fraczek, M. G., Kirwan, M., Gore, R., Smith, J., Bueid, A., Moore, C. B., Bowyer, P., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir179 · Cited by 313
Cited by
Antifungal Susceptibility Testing: Current Approaches
Berkow, E. L., Lockhart, S. R., & Ostrosky-Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 368
Clinical implications of globally emerging azole resistance in Aspergillus fumigatus
Meis, J. F., Chowdhary, A., Rhodes, J. L., Fisher, M. C., & Verweij, P. E. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0460 · Cited by 308
Self-citationDrug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment
Chowdhary, A., Sharma, C., & Meis, J. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix210 · Cited by 262
Self-citationEmerging threat of triazole-resistant Aspergillus fumigatus
Rybak, J. M., Fortwendel, J. R., & Rogers, P. D. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky517 · Cited by 80
Metadata
- Authors
- Lestrade, P. P. A., Meis, J. F., Arends, J. P., van der Beek, M. T., de Brauwer, E., van Dijk, K., de Greeff, S. C., Haas, P., Hodiamont, C. J., Kuijper, E. J., Leenstra, T., Muller, A. E., Oude Lashof, A. M. L., Rijnders, B. J., Roelofsen, E., Rozemeijer, W., Tersmette, M., Terveer, E. M., Verduin, C. M., Wolfhagen, M. J. H. M., Melchers, W. J. G., & Verweij, P. E.
- Venue
- Mycoses
- Publisher
- Wiley
- Published
- 2015-12-09
- Volume
- 59
- Issue
- 2
- Pages
- 101-107
- ISSN
- 0027-5557 (ISSN-L)
- 0933-7407
- 1439-0507
- OpenAlex
- W2196289109
- Cited by
- 40
- References
- 5
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.